What is Pemigatinib?

Fibroblast growth factor receptorSmall molecule inhibitor of (FGFR)1, FGFR2 and FGFR3Pemigatinib (Pemigatinib) was approved in the United States in April 2020 Immediate approval for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma (CCA) and FGFR2 fusions or other rearrangements as detected by a U.S. Food and Drug Administration (FDA) approved trial.

Pemetinib, developed byIncyte, is the first targeted therapy for cholangiocarcinoma in the United States. Its recommended dose is 13.5 mg once daily on days 1-14 of a 21-day cycle, which can be administered orally with or without food until disease progression or unacceptable toxicity. Pemetinib has orphan designation in the United States for the treatment of myeloid/lymphoid tumors with eosinophilia and rearrangements of PDGFRA, PDGFRB, or FGFR1, or myeloid/lymphoid tumors with PCM1-JAK2.

The original drug of pemetinib has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. The price of each box of 4.5mg*14 tablets may be around 30,000 yuan, which is expensive. The price of the original pemetinib drug, 13.5mg*14 tablets, per box sold overseas may be around RMB 70,000 (the price may fluctuate due to exchange rates). There are also generic pemetinib drugs produced in other countries overseas. For example, the price of a box of 4.5mg*21 tablets produced by a Laos pharmaceutical factory may be around 3,000 yuan (the price may fluctuate due to the exchange rate). The price is relatively cheap. The pharmaceutical ingredients of the generic drugs are basically the same as those of the original drugs at home and abroad.